Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07065331 · ClinicalTrials.gov registry record · Phase 1
A Study of Inhaled AZD8630 in Adolescents With Asthma
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT07065331 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 10 participants.
The verdict
NCT07065331, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, tolerability, and immunogenicity of single inhaled dose of AZD8630 administered in adolescent participants with asthma as well as the safety and performance of the dry powder inhaler.
Interventions
- DRUG AZD8630
- DEVICE Dry powder inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2025-09-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07065331
The ClinicalTrials.gov registry entry for NCT07065331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD8630 is the first listed.
NCT07065331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07065331 about?
NCT07065331 is a clinical study titled "A Study of Inhaled AZD8630 in Adolescents With Asthma". The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, tolerability, and immunogenicity of single inhaled dose of AZD8630 administered in adolescent participants with asthma as well as the safety and performance of the dry powder inhaler.
What is the current status of trial NCT07065331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-06-11. Estimated completion is 2025-09-19.
What interventions are being tested in trial NCT07065331?
The interventions under investigation include: AZD8630 (DRUG), Dry powder inhaler (DEVICE).
Who is sponsoring clinical trial NCT07065331?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.